Table 4.
The novelty of the positive signals of DILI.
| Drug ID | Drugs | Literature (PUBMED)a | Literature (CNKI/Wanfang) | SPCsb | ||
|---|---|---|---|---|---|---|
| Adults | Children | Adults | Children | |||
| 1 | Fluconazole | Yes | Yes | Yes | No | Yesc |
| 2 | Omeprazole | Yes | Yes | Yes | No | Yes |
| 3 | Sulfamethoxazole | Yes | Yes | Yes | Yes | Yes |
| 4 | Vancomycin | Yes | Yes | Yes | Yes | Yes |
| 5 | G-CSF | No | No | No | No | Yes |
| 6 | Acetaminophen | Yes | Yes | Yes | Yes | Yes |
| 7 | Nifedipine | Yes | No | Yes | No | Yes |
| 8 | Fusidine | Yes | No | Yes | No | Yes |
| 9 | Oseltamivir | Yes | No | Yes | No | Yes |
| 10 | Nystatin | No | No | No | No | No |
| 11 | Meropenem | Yes | Yes | Yes | Yes | Yes |
Literature reviewed: (1) PUBMED: https://pubmed.ncbi.nlm.nih.gov; (2) Wanfang: http://www.wanfangdata.com.cn/index.html); (3) CNKI: https://www.cnki.net.
SPCs reviewed: (1) Micromedex: https://www.ibm.com/watson-health/learn/micromedex); (2) FDA website: https://www.fda.gov/; (3) Drug instructions.
Yes = drug–DILI association was documented.
DILI, drug–induced liver injury; G-CSF, granu1ocyte colony-stimulating factor; SPC, summary of product characteristics.